[HTML][HTML] Linaclotide in chronic idiopathic constipation patients with moderate to severe abdominal bloating: a randomized, controlled trial
BE Lacy, R Schey, SJ Shiff, BJ Lavins, SM Fox, XD Jia… - PLoS …, 2015 - journals.plos.org
BE Lacy, R Schey, SJ Shiff, BJ Lavins, SM Fox, XD Jia, RE Blakesley, X Hao, JA Cronin…
PLoS One, 2015•journals.plos.orgBackground Abdominal bloating is a common and bothersome symptom of chronic
idiopathic constipation. The objective of this trial was to evaluate the efficacy and safety of
linaclotide in patients with chronic idiopathic constipation and concomitant moderate-to-
severe abdominal bloating. Methods This Phase 3b, randomized, double-blind, placebo-
controlled clinical trial randomized patients to oral linaclotide (145 or 290 μg) or placebo
once daily for 12 weeks. Eligible patients met Rome II criteria for chronic constipation upon …
idiopathic constipation. The objective of this trial was to evaluate the efficacy and safety of
linaclotide in patients with chronic idiopathic constipation and concomitant moderate-to-
severe abdominal bloating. Methods This Phase 3b, randomized, double-blind, placebo-
controlled clinical trial randomized patients to oral linaclotide (145 or 290 μg) or placebo
once daily for 12 weeks. Eligible patients met Rome II criteria for chronic constipation upon …
Background
Abdominal bloating is a common and bothersome symptom of chronic idiopathic constipation. The objective of this trial was to evaluate the efficacy and safety of linaclotide in patients with chronic idiopathic constipation and concomitant moderate-to-severe abdominal bloating.
Methods
This Phase 3b, randomized, double-blind, placebo-controlled clinical trial randomized patients to oral linaclotide (145 or 290 μg) or placebo once daily for 12 weeks. Eligible patients met Rome II criteria for chronic constipation upon entry with an average abdominal bloating score ≥5 (self-assessment: 0 10-point numerical rating scale) during the 14-day baseline period. Patients reported abdominal symptoms (including bloating) and bowel symptoms daily; adverse events were monitored. The primary responder endpoint required patients to have ≥3 complete spontaneous bowel movements/week with an increase of ≥1 from baseline, for ≥9 of 12 weeks. The primary endpoint compared linaclotide 145 μg vs. placebo.
Results
The intent-to-treat population included 483 patients (mean age=47.3 years, female=91.5%, white=67.7%). The primary endpoint was met by 15.7% of linaclotide 145 μg patients vs. 7.6% of placebo patients (P<0.05). Both linaclotide doses significantly improved abdominal bloating vs. placebo (P<0.05 for all secondary endpoints, controlling for multiplicity). Approximately one-third of linaclotide patients (each group) had ≥50% mean decrease from baseline in abdominal bloating vs. 18% of placebo patients (P<0.01). Diarrhea was reported in 6% and 17% of linaclotide 145 and 290 μg patients, respectively, and 2% of placebo patients. AEs resulted in premature discontinuation of 5% and 9% of linaclotide 145 μg and 290 μg patients, respectively, and 6% of placebo patients.
Conclusions
Once-daily linaclotide (145 and 290 μg) significantly improved bowel and abdominal symptoms in chronic idiopathic constipation patients with moderate-to-severe baseline abdominal bloating; in particular, linaclotide significantly improved abdominal bloating compared to placebo, an important finding given the lack of agents available to treat abdominal bloating in chronic idiopathic constipation patients.
Trial Registration
ClinicalTrials.gov NCT01642914
PLOS